We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+41.99%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
-$1.2B
Cap. Flow %
-17.09%
Top 10 Hldgs %
79.89%
Holding
87
New
12
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$51.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.5M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$16.6M
4
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.7M
5
XOMA
Xoma
XOMA
+$12.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$195M
2
VPHM
VIROPHARMA INC
VPHM
+$96M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$15.8M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$8.82M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 42.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
51
United Therapeutics
UTHR
$26B
$4.41M 0.06%
+55,984
New +$4.09M
LITS
52
Lite Strategy Inc
LITS
$32.4M
$3.88M 0.06%
17,266
-8,515
-33% -$1.33M
ZGNX
53
DELISTED
Zogenix, Inc.
ZGNX
$3.7M 0.05%
250,125
– –
ASMB icon
54
Assembly Biosciences
ASMB
$494M
$3.51M 0.05%
20,264
– –
GERN icon
55
Geron
GERN
$924M
$3.35M 0.05%
1,058,000
– –
LGND icon
56
Ligand Pharmaceuticals
LGND
$5.79B
$3.18M 0.05%
117,660
– –
MDGL icon
57
Madrigal Pharmaceuticals
MDGL
$12.5B
$3.15M 0.04%
14,286
-25,687
-64% -$5.46M
TGTX icon
58
TG Therapeutics
TGTX
$8.29B
$3.02M 0.04%
+600,000
New +$3.67M
BLUE
59
DELISTED
bluebird bio
BLUE
$3.01M 0.04%
+8,609
New +$3.2M
WINT
60
DELISTED
Windtree Therapeutics Inc
WINT
$2.98M 0.04%
108,473
– –
ENTA icon
61
Enanta Pharmaceuticals
ENTA
$365M
$2.87M 0.04%
125,000
– –
RCPT
62
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.6M 0.04%
100,000
– –
SGMO
63
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.85M 0.03%
+176,707
New +$1.75M
RIGL icon
64
Rigel Pharmaceuticals
RIGL
$731M
$1.79M 0.03%
+50,000
New +$1.82M
OSUR icon
65
OraSure Technologies
OSUR
$273M
$1.46M 0.02%
243,467
– –
ACHN
66
DELISTED
Achillion Pharmaceuticals
ACHN
$1.37M 0.02%
455,000
– –
TSRO
67
DELISTED
TESARO, Inc.
TSRO
$1.21M 0.02%
31,218
– –
FOLD
68
DELISTED
Amicus Therapeutics
FOLD
$1.2M 0.02%
515,072
– –
CCXI
69
DELISTED
ChemoCentryx, Inc.
CCXI
$1.11M 0.02%
200,000
-175,000
-47% -$1.89M
TCRT icon
70
Alaunos Therapeutics
TCRT
$4.69M
$1M 0.01%
1,695
– –
EPZM
71
DELISTED
Epizyme, Inc
EPZM
$800K 0.01%
20,000
– –
CBST
72
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$318K ﹤0.01%
5,000
– –
SLXP
73
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$242K ﹤0.01%
3,621
-41,950
-92% -$2.89M
APEN
74
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-2,597
Closed -$880K
ALBO
75
DELISTED
Albireo Pharma Inc
ALBO
– –
-7,663
Closed -$961K
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2013 Portfolio in Review

As of Q3 2013, Baker Bros. Advisors held 87 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors withdrew a net $1.2B in Q3 2013, closing 5 positions and reducing 15 holdings. Its most notable exit was Arqule Inc, an estimated $2.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Mirati Therapeutics, Inc. Common Stock worth $30M.

  • Baker Bros. Advisors's largest Q3 2013 buy was Mirati Therapeutics, Inc. Common Stock: 1,980,074 shares worth $30M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $51.7M increase.
  • Baker Bros. Advisors's biggest Q3 2013 reduction was PHARMACYCLICS INC, cutting an estimated $195M.
  • Baker Bros. Advisors fully exited Arqule Inc in Q3 2013, selling an estimated $2.04M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $7.04B portfolio in Q3 2013.
  • Baker Bros. Advisors opened 12 new positions and closed 5 in Q3 2013.
  • Baker Bros. Advisors's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Baker Bros. Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.